News

Kaléo Announces First U.S. Department of Defense Supply Contract for the Rapid Opioid Countermeasure System (ROCS) Antidote for Ultra-Potent Weaponized Opioids

Kaléo, a privately held commercial-stage U.S. pharmaceutical company, announced the execution of the first contract with the U.S. Department of Defense (DoD) for the procurement of the Rapid Opioid Countermeasure System (ROCS), a 10 mg Naloxone Auto-injector (naloxone hydrochloride injection) antidote for ultra-potent weaponized opioids. The contract includes an award for the manufacture and delivery of up to 788,000 units.

“ROCS was developed to protect and maintain the readiness of the Joint Force and our NATO allies,” said Colonel Matthew Clark, PhD, PMP, the Joint Project Manager for CBRN Medical. “Weaponized synthetic opioids, such as fentanyl and carfentanyl, have been used operationally in the past and continue to pose a unique threat to our service members. This first delivery of ROCS auto-injectors is a great achievement.”

Kaléo was awarded the prototype development contract for the ROCS program in 2018 by the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical), a component of the U.S. Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) in collaboration with the Chemical and Biological Defense Program (CBDP). The JPM CBRN Medical facilitates the advanced development and acquisition of medical countermeasures (MCM) and systems to enhance the nation’s CBRN response capability.

“This first DoD procurement contract is a major milestone for Kaléo,” said Mark A. Herzog, the company’s vice president, global corporate affairs, defense and homeland security. “We are pleased to have delivered ROCS under budget, and five months ahead of schedule, despite challenges presented by the pandemic and disruptions to the global supply chain.”

Approved by the U.S. Food and Drug Administration (FDA) on February 28, 2022, ROCS is a 10 mg Naloxone Auto-injector (naloxone hydrochloride injection) indicated for the emergency treatment of people 12 years of age and older where use of high-potency opioids such as fentanyl analogues as a chemical weapon, is suspected. See full indication below.

Additionally, the Naloxone Auto-injector 10 mg is indicated for the temporary prevention (prophylaxis) of either breathing problems (respiratory depression), decreased brain and nerve function (central nervous system depression), or both, in military personnel and chemical incident responders entering an area contaminated with high-potency opioids such as fentanyl analogues.

The New Drug Application for the Naloxone Auto-injector 10 mg was submitted on August 31, 2021 and was granted Fast Track Designation by the FDA. In addition to more than 150 performance verification tests, the ROCS Naloxone Auto-injector 10 mg underwent military standard testing and evaluation for suitability on behalf of the JPM CBRN Medical which included three cumulative shock tests and seven cumulative environmental tests. The ROCS Naloxone Auto-injector 10 mg also meets the U.S. Food and Drug Administration (FDA) draft guidance standard for 99.999% device reliability.

 

Click here to learn more.

Recent News

02/01/2023

Engineered BioPharmaceuticals to Expand in Virginia

Governor Glenn Youngkin announced that Engineered BioPharmaceuticals, Inc., a pharmaceutical engineering and manufacturing company dedicated to advancing cost effective, state-of-the-art medicine, will invest $6.1 million to expand in the City of Danville. The company will expand from its current lab space in the Dan River Business Development Center into its first standalone manufacturing facility at

02/01/2023

Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, announced it has entered into an option agreement for the sale of the assets of Purnovate, Inc. (“Purnovate”), a wholly owned subsidiary of Adial, to Adenomed, LLC (“Adenomed”), a new company formed by Purnovate

01/31/2023

AMPEL BioSolutions’ Breakthrough Predicts Drug Options for Fibromyalgia

AMPEL BioSolutions announced a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat chronic pain syndromes, such as fibromyalgia. Revealed in the peer-reviewed journal Lupus Science and Medicine, the paper details AMPEL’s breakthrough approach to characterize the underlying disease activity from gene expression data obtained from patient blood samples. The FibroGENE® lab